Eculizumab Biosimilar – Anti-C5 mAb – Research Grade

Description of Eculizumab Biosimilar - Anti-C5 mAb - Research Grade

Introduction

Eculizumab biosimilar, also known as Anti-C5 mAb, is a research grade monoclonal antibody that targets the C5 protein in the complement system. It is a biosimilar version of the FDA-approved drug Eculizumab, which is used for the treatment of various complement-mediated disorders. In this article, we will discuss the structure, activity, and potential applications of Eculizumab biosimilar as a therapeutic antibody.

Structure of Eculizumab Biosimilar

Eculizumab biosimilar is a recombinant humanized monoclonal antibody that is composed of two heavy chains and two light chains. The heavy chains consist of four constant domains (CH1, CH2, CH3, and CH4) and one variable domain (VH), while the light chains consist of two constant domains (CL) and one variable domain (VL). The variable domains of both the heavy and light chains are responsible for binding to the C5 protein.

Activity of Eculizumab Biosimilar

Eculizumab biosimilar works by inhibiting the activity of the C5 protein in the complement system. The complement system is a part of the immune system that helps in fighting against infections and foreign substances. However, in some diseases, the complement system becomes overactive and can cause damage to healthy tissues. This is where Eculizumab biosimilar comes into play. It binds to the C5 protein, preventing it from being activated and thus, stopping the downstream cascade of the complement system. This ultimately reduces the inflammation and tissue damage caused by an overactive complement system.

Applications of Eculizumab Biosimilar

Eculizumab biosimilar has shown promising results in the treatment of various complement-mediated disorders, including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). PNH is a rare blood disorder characterized by the breakdown of red blood cells, while aHUS is a rare kidney disease caused by an overactive complement system. Eculizumab biosimilar has been approved by the FDA for the treatment of both these diseases.

In addition to PNH and aHUS, Eculizumab biosimilar is also being studied for its potential use in other complement-mediated disorders, such as myasthenia gravis, neuromyelitis optica spectrum disorder, and Guillain-Barré syndrome. These diseases are characterized by the abnormal activation of the complement system, leading to tissue damage and inflammation. By targeting the C5 protein, Eculizumab biosimilar has the potential to provide a novel treatment approach for these disorders.

Conclusion

In summary, Eculizumab biosimilar is a research grade monoclonal antibody that targets the C5 protein in the complement system. It works by inhibiting the activity of C5 and has shown promising results in the treatment of various complement-mediated disorders. With its potential to provide a novel treatment approach, Eculizumab biosimilar holds great promise in the field of therapeutic antibodies. Further research and clinical trials are needed to fully understand its potential and expand its applications in the treatment of various diseases.

Eculizumab Biosimilar - Anti-C5 mAb binds to Human C5 in indirect ELISA Assay

Immobilized Human C5 recombinant protein (cat. No. PX-P5117) at 0.5µg/mL (100µL/well) can bind Eculizumab Biosimilar - Anti-C5 mAb (cat. No. PX-TA1039) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450 giving an EC50 at 201.0M.